Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report

A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kayo, Tsubamoto, Hiroshi, Ueda, Tomoko, Tajima, Chihiro, Nakagomi, Nami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152717/
https://www.ncbi.nlm.nih.gov/pubmed/32300630
http://dx.doi.org/10.1016/j.gore.2020.100563
_version_ 1783521538953183232
author Inoue, Kayo
Tsubamoto, Hiroshi
Ueda, Tomoko
Tajima, Chihiro
Nakagomi, Nami
author_facet Inoue, Kayo
Tsubamoto, Hiroshi
Ueda, Tomoko
Tajima, Chihiro
Nakagomi, Nami
author_sort Inoue, Kayo
collection PubMed
description A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to olaparib in a patient with uterine serous carcinoma and a germline pathogenic BRCA2 variant.
format Online
Article
Text
id pubmed-7152717
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-71527172020-04-16 Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report Inoue, Kayo Tsubamoto, Hiroshi Ueda, Tomoko Tajima, Chihiro Nakagomi, Nami Gynecol Oncol Rep Case Report A germline pathogenic variant in BRCA2 was secondarily found through genomic sequencing of uterine serous carcinoma. Clinical response to olaparib was observed in recurrent uterine serous carcinoma with a germline BRCA2 mutation. Here, we report, for the first time, a long-term clinical response to olaparib in a patient with uterine serous carcinoma and a germline pathogenic BRCA2 variant. Elsevier 2020-04-05 /pmc/articles/PMC7152717/ /pubmed/32300630 http://dx.doi.org/10.1016/j.gore.2020.100563 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Inoue, Kayo
Tsubamoto, Hiroshi
Ueda, Tomoko
Tajima, Chihiro
Nakagomi, Nami
Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title_full Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title_fullStr Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title_full_unstemmed Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title_short Recurrent uterine serous carcinoma with a germline pathogenic BRCA2 variant treated using olaparib: A case report
title_sort recurrent uterine serous carcinoma with a germline pathogenic brca2 variant treated using olaparib: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152717/
https://www.ncbi.nlm.nih.gov/pubmed/32300630
http://dx.doi.org/10.1016/j.gore.2020.100563
work_keys_str_mv AT inouekayo recurrentuterineserouscarcinomawithagermlinepathogenicbrca2varianttreatedusingolaparibacasereport
AT tsubamotohiroshi recurrentuterineserouscarcinomawithagermlinepathogenicbrca2varianttreatedusingolaparibacasereport
AT uedatomoko recurrentuterineserouscarcinomawithagermlinepathogenicbrca2varianttreatedusingolaparibacasereport
AT tajimachihiro recurrentuterineserouscarcinomawithagermlinepathogenicbrca2varianttreatedusingolaparibacasereport
AT nakagominami recurrentuterineserouscarcinomawithagermlinepathogenicbrca2varianttreatedusingolaparibacasereport

Ejemplares similares